{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:21:44Z","timestamp":1794036104442,"version":"4.8.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s11906-017-0754-x","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T06:51:44Z","timestamp":1496904704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Resistant Hypertension: Mechanisms and Treatment"],"prefix":"10.1007","volume":"19","author":[{"given":"Andrew Y.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"754_CR1","first-page":"2741","volume-title":"Hypertension: pathophysiology, diagnosis, and management","author":"ED Freis","year":"1995","unstructured":"Freis ED. Historical development of antihypertensive treatment. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. p. 2741\u201351.","edition":"2nd"},{"issue":"3","key":"754_CR2","first-page":"137","volume":"47","author":"J Hakkila","year":"1958","unstructured":"Hakkila J. Use of oxaditon in cases of reserpine-resistant hypertension. Ann Med Intern Fenn. 1958;47(3):137\u201346.","journal-title":"Ann Med Intern Fenn"},{"issue":"5","key":"754_CR3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.7326\/0003-4819-88-5-661","volume":"88","author":"RW Gifford Jr","year":"1978","unstructured":"Gifford RW Jr, Tarazi RC. Resistant hypertension: diagnosis and management. Ann Intern Med. 1978;88(5):661\u20135.","journal-title":"Ann Intern Med"},{"issue":"19","key":"754_CR4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003;289(19):2560\u201372.","journal-title":"Jama"},{"key":"754_CR5","doi-asserted-by":"crossref","unstructured":"European Society of Hypertension-European Society of Cardiology Guideline Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6):1011\u201353.","DOI":"10.1097\/00004872-200306000-00001"},{"issue":"25","key":"754_CR6","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510\u201326.","journal-title":"Circulation"},{"issue":"6","key":"754_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","volume":"8","author":"MR Irvin","year":"2014","unstructured":"Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8(6):405\u201313.","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"754_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjmed.2013.07.038","volume":"127","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127(1):71\u201381.e71.","journal-title":"Am J Med"},{"issue":"3","key":"754_CR9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/HJH.0000000000000051","volume":"32","author":"SM Smith","year":"2014","unstructured":"Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635\u201343.","journal-title":"J Hypertens"},{"issue":"5","key":"754_CR10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","volume":"64","author":"P Muntner","year":"2014","unstructured":"Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64(5):1012\u201321.","journal-title":"Hypertension"},{"issue":"24","key":"754_CR11","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","volume":"61","author":"L Nicola De","year":"2013","unstructured":"De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J am Coll Cardiol. 2013;61(24):2461\u20137.","journal-title":"J am Coll Cardiol"},{"issue":"16","key":"754_CR12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/eurheartj\/ehs368","volume":"34","author":"DJ Kumbhani","year":"2013","unstructured":"Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204\u201314.","journal-title":"Eur Heart J"},{"issue":"3","key":"754_CR13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/jhh.2015.61","volume":"30","author":"NW Carris","year":"2016","unstructured":"Carris NW, Ghushchyan V, Libby AM, Smith SM. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. J hum Hypertens. 2016;30(3):191\u20136.","journal-title":"J hum Hypertens"},{"issue":"4","key":"754_CR14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/HJH.0b013e32835ebdd7","volume":"31","author":"M Zygmuntowicz","year":"2013","unstructured":"Zygmuntowicz M, Owczarek A, Elibol A, Olszanecka-Glinianowicz M, Chudek J. Blood pressure for optimal health-related quality of life in hypertensive patients. J Hypertens. 2013;31(4):830\u20139.","journal-title":"J Hypertens"},{"key":"754_CR15","doi-asserted-by":"crossref","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association. Circulation. 2017.","DOI":"10.1161\/CIR.0000000000000485"},{"issue":"6","key":"754_CR16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"1","key":"754_CR17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrneph.2012.260","volume":"9","author":"PA Sarafidis","year":"2013","unstructured":"Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension\u2014its identification and epidemiology. Nat Rev Nephrol. 2013;9(1):51\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"13","key":"754_CR18","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"issue":"5","key":"754_CR19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cjca.2015.06.033","volume":"32","author":"M Siddiqui","year":"2016","unstructured":"Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32(5):603\u20136.","journal-title":"Can J Cardiol"},{"issue":"6","key":"754_CR20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/HYPERTENSIONAHA.116.06587","volume":"67","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension. 2016;67(6):1085\u201392.","journal-title":"Hypertension"},{"issue":"5","key":"754_CR21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2016080927","volume":"28","author":"W Feng","year":"2017","unstructured":"Feng W, Dell\u2019Italia LJ, Sanders PW. Novel paradigms of salt and hypertension. J Am Soc Nephrol. 2017;28(5):1362\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"754_CR22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475\u201381.","journal-title":"Hypertension"},{"issue":"5","key":"754_CR23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"SJ Taler","year":"2002","unstructured":"Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982\u20138.","journal-title":"Hypertension"},{"issue":"5 Pt 1","key":"754_CR24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","volume":"18","author":"JP Garg","year":"2005","unstructured":"Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5 Pt 1):619\u201326.","journal-title":"Am J Hypertens"},{"issue":"3","key":"754_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0895-7061(02)03260-0","volume":"16","author":"HL Vlase","year":"2003","unstructured":"Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. Am J Hypertens. 2003;16(3):187\u201393.","journal-title":"Am J Hypertens"},{"issue":"11","key":"754_CR26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern med. 2008;168(11):1159\u201364.","journal-title":"Arch Intern med"},{"key":"754_CR27","doi-asserted-by":"crossref","first-page":"929183","DOI":"10.1155\/2013\/929183","volume":"2013","author":"S Borrelli","year":"2013","unstructured":"Borrelli S, De Nicola L, Stanzione G, Conte G, Minutolo R. Resistant hypertension in nondialysis chronic kidney disease. Int J Hypertens. 2013;2013:929183.","journal-title":"Int J Hypertens"},{"key":"754_CR28","doi-asserted-by":"crossref","first-page":"143471","DOI":"10.4061\/2011\/143471","volume":"2011","author":"Z Khawaja","year":"2011","unstructured":"Khawaja Z, Wilcox CS. Role of the kidneys in resistant hypertension. Int J Hypertens. 2011;2011:143471.","journal-title":"Int J Hypertens"},{"issue":"7","key":"754_CR29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gft346","volume":"29","author":"YR Drexler","year":"2014","unstructured":"Drexler YR, Bomback AS. Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. Nephrol Dial Transplant. 2014;29(7):1327\u201335.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"754_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11906-017-0713-6","volume":"19","author":"TH Jemtel Le","year":"2017","unstructured":"Le Jemtel TH, Richardson W, Samson R, Jaiswal A, Oparil S. Pathophysiology and potential non-pharmacologic treatments of obesity or kidney disease associated refractory hypertension. Curr Hypertens Rep. 2017;19(2):18.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"754_CR31","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","volume":"116","author":"JE Hall","year":"2015","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991\u20131006.","journal-title":"Circ Res"},{"issue":"6","key":"754_CR32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Riet Te","year":"2015","unstructured":"Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960\u201375.","journal-title":"Circ Res"},{"issue":"8","key":"754_CR33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/hr.2013.69","volume":"36","author":"T Shimosawa","year":"2013","unstructured":"Shimosawa T. Salt, the renin-angiotensin-aldosterone system and resistant hypertension. Hypertens Res. 2013;36(8):657\u201360.","journal-title":"Hypertens Res"},{"issue":"7","key":"754_CR34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","volume":"33","author":"U Forstermann","year":"2012","unstructured":"Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829\u201337.","journal-title":"Eur Heart J"},{"issue":"8","key":"754_CR35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/dna.2010.1156","volume":"30","author":"JC Yugar-Toledo","year":"2011","unstructured":"Yugar-Toledo JC, Martin JF, Krieger JE, et al. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011;30(8):555\u201364.","journal-title":"DNA Cell Biol"},{"issue":"5","key":"754_CR36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.semnephrol.2014.08.007","volume":"34","author":"EK Judd","year":"2014","unstructured":"Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014;34(5):532\u20139.","journal-title":"Semin Nephrol"},{"issue":"4","key":"754_CR37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5664\/jcsm.27878","volume":"6","author":"CC Gonzaga","year":"2010","unstructured":"Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363\u20138.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"754_CR38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark 3rd","year":"2012","unstructured":"Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28(3):318\u201325.","journal-title":"Can J Cardiol"},{"issue":"11","key":"754_CR39","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217\u201326.","journal-title":"J Hypertens"},{"issue":"3","key":"754_CR40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150(3):426\u201333.","journal-title":"Am Heart J"},{"key":"754_CR41","doi-asserted-by":"crossref","first-page":"242786","DOI":"10.1155\/2012\/242786","volume":"2012","author":"H Takahashi","year":"2012","unstructured":"Takahashi H. Upregulation of the renin-angiotensin-aldosterone-ouabain system in the brain is the core mechanism in the genesis of all types of hypertension. Int J Hypertens. 2012;2012:242786.","journal-title":"Int J Hypertens"},{"issue":"6","key":"754_CR42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCRESAHA.116.303604","volume":"116","author":"G Grassi","year":"2015","unstructured":"Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ res. 2015;116(6):976\u201390.","journal-title":"Circ res"},{"issue":"3","key":"754_CR43","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1161\/HYPERTENSIONAHA.113.02439","volume":"63","author":"M Esler","year":"2014","unstructured":"Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. Hypertension. 2014;63(3):e25\u201332.","journal-title":"Hypertension"},{"issue":"3","key":"754_CR44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/HJH.0000000000000068","volume":"32","author":"GF Salles","year":"2014","unstructured":"\u2022 Salles GF, Ribeiro FM, Guimaraes GM, Muxfeldt ES, Cardoso CR. A reduced heart rate variability is independently associated with a blunted nocturnal blood pressure fall in patients with resistant hypertension. J Hypertens. 2014;32(3):644\u201351. This cross-sectional study found potential association of SNS activity with a blunted nocturnal BP fall in resistant hypertension.","journal-title":"J Hypertens"},{"issue":"10","key":"754_CR45","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/diacare.24.10.1793","volume":"24","author":"J Gerritsen","year":"2001","unstructured":"Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn study. Diabetes Care. 2001;24(10):1793\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"754_CR46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","volume":"66","author":"T Dudenbostel","year":"2015","unstructured":"\u2022\u2022 Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126\u201333. This study identified several markers of elevated SNS activity associated with the refractory hypertension phenotype.","journal-title":"Hypertension"},{"issue":"40","key":"754_CR47","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/eurheartj\/ehv392","volume":"36","author":"SF Rimoldi","year":"2015","unstructured":"Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686\u201395.","journal-title":"Eur Heart J"},{"issue":"3","key":"754_CR48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCRESAHA.115.307722","volume":"118","author":"JD Humphrey","year":"2016","unstructured":"Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: a problem with cause and consequence. Circ Res. 2016;118(3):379\u201381.","journal-title":"Circ Res"},{"issue":"1","key":"754_CR49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11906-017-0704-7","volume":"19","author":"JE Sharman","year":"2017","unstructured":"Sharman JE, Boutouyrie P, Laurent S. Arterial (aortic) stiffness in patients with resistant hypertension: from assessment to treatment. Curr Hypertens Rep. 2017;19(1):2.","journal-title":"Curr Hypertens Rep"},{"issue":"1 Suppl 1","key":"754_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1524-6175.2007.06367.x","volume":"9","author":"DA Duprez","year":"2007","unstructured":"Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(1 Suppl 1):13\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"754_CR51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11906-017-0726-1","volume":"19","author":"S Xiong","year":"2017","unstructured":"Xiong S, Li Q, Liu D, Zhu Z. Gastrointestinal tract: a promising target for the management of hypertension. Curr Hypertens Rep. 2017;19(4):31.","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"754_CR52","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/CIRCRESAHA.116.307709","volume":"118","author":"MM Santisteban","year":"2016","unstructured":"Santisteban MM, Kim S, Pepine CJ, Raizada MK. Brain-gut-bone marrow axis: implications for hypertension and related therapeutics. Circ Res. 2016;118(8):1327\u201336.","journal-title":"Circ Res"},{"issue":"4","key":"754_CR53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11906-017-0734-1","volume":"19","author":"EM Richards","year":"2017","unstructured":"Richards EM, Pepine CJ, Raizada MK, Kim S. The gut, its microbiome, and hypertension. Curr Hypertens Rep. 2017;19(4):36.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"754_CR54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCRESAHA.116.309006","volume":"120","author":"MM Santisteban","year":"2017","unstructured":"Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, et al. Hypertension-linked pathophysiologic alterations in the gut. Circ Res. 2017;120(2):312\u201323.","journal-title":"Circ Res"},{"key":"754_CR55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2015.07.078","volume":"201","author":"Y Qi","year":"2015","unstructured":"Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension\u2014a case report. Int J Cardiol. 2015;201:157\u20138.","journal-title":"Int J Cardiol"},{"issue":"1","key":"754_CR56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2011.05.024","volume":"125","author":"E Grossman","year":"2012","unstructured":"Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125(1):14\u201322.","journal-title":"Am J Med"},{"issue":"19","key":"754_CR57","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/eht534","volume":"35","author":"SF Rimoldi","year":"2014","unstructured":"Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245\u201354.","journal-title":"Eur Heart J"},{"issue":"20","key":"754_CR58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","volume":"32","author":"PS Sever","year":"2011","unstructured":"Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499\u2013506.","journal-title":"Eur Heart J"},{"issue":"6","key":"754_CR59","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","volume":"68","author":"AY Hwang","year":"2016","unstructured":"Hwang AY, Dave C, Smith SM. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016;68(6):1349\u201354.","journal-title":"Hypertension"},{"issue":"1","key":"754_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14\u201326.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"754_CR61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507\u201320.","journal-title":"Jama"},{"issue":"22","key":"754_CR62","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra0907219","volume":"361","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J med. 2009;361(22):2153\u201364.","journal-title":"N Engl J med"},{"issue":"6","key":"754_CR63","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/HYPERTENSIONAHA.112.191106","volume":"59","author":"GC Roush","year":"2012","unstructured":"Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110\u20137.","journal-title":"Hypertension"},{"issue":"4","key":"754_CR64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","volume":"57","author":"MP Dorsch","year":"2011","unstructured":"Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689\u201394.","journal-title":"Hypertension"},{"issue":"10008","key":"754_CR65","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"\u2022\u2022 Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368. This randomized, controlled trial found superior BP-lowering with spironolactone compared to doxazosin, bisoprolol, and placebo among patients with resistant hypertension on an A + C + D regimen.","journal-title":"Lancet"},{"issue":"6","key":"754_CR66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","volume":"2","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J am Soc Hypertens. 2008;2(6):462\u20138.","journal-title":"J am Soc Hypertens"},{"key":"754_CR67","doi-asserted-by":"crossref","first-page":"d4891","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.","journal-title":"BMJ"},{"key":"754_CR68","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC practice guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"issue":"4","key":"754_CR69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11906-017-0728-z","volume":"19","author":"HC Prosser","year":"2017","unstructured":"Prosser HC, Gregory C, Hering D, et al. Preferred fourth-line pharmacotherapy for resistant hypertension: are we there yet? Curr Hypertens Rep. 2017;19(4):30.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"754_CR70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CRD.0b013e31825d0a44","volume":"20","author":"T Dudenbostel","year":"2012","unstructured":"Dudenbostel T, Glasser SP. Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev. 2012;20(5):259\u201363.","journal-title":"Cardiol Rev"},{"issue":"8","key":"754_CR71","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","volume":"30","author":"G Bobrie","year":"2012","unstructured":"Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656\u201364.","journal-title":"J Hypertens"},{"issue":"1","key":"754_CR72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13063-017-1863-1","volume":"18","author":"GR Constantine","year":"2017","unstructured":"Constantine GR, Ranasinghe P, Weeratunga P, et al. Addition of propranolol in resistant arterial hypertension treatment (APROPRIATE study): a study protocol for a randomized double-blind placebo-controlled trial. Trials. 2017;18(1):124.","journal-title":"Trials"},{"issue":"15","key":"754_CR73","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT Collaborative Research Group","year":"2000","unstructured":"ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama. 2000;283(15):1967\u201375.","journal-title":"Jama"},{"issue":"1\u20132","key":"754_CR74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08037050902843726","volume":"18","author":"J Ceral","year":"2009","unstructured":"Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009;18(1\u20132):74\u20137.","journal-title":"Blood Press"},{"issue":"2","key":"754_CR75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0300-8932(09)70158-7","volume":"62","author":"E Rodilla","year":"2009","unstructured":"Rodilla E, Costa JA, Perez-Lahiguera F, Baldo E, Gonzalez C, Pascual JM. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009;62(2):158\u201366.","journal-title":"Rev Esp Cardiol"},{"key":"754_CR76","volume":"11","author":"MR Kandler","year":"2011","unstructured":"Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2011;11:CD004934.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"754_CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/pgs.13.202","volume":"15","author":"LB Spinasse","year":"2014","unstructured":"Spinasse LB, Santos AR, Suffys PN, Muxfeldt ES, Salles GF. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics. 2014;15(2):169\u201378.","journal-title":"Pharmacogenomics"},{"issue":"11","key":"754_CR78","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/jch.12847","volume":"18","author":"HM Mundt","year":"2016","unstructured":"\u2022 Mundt HM, Matenaer M, Lammert A, et al. Minoxidil for treatment of resistant hypertension in chronic kidney disease\u2014a retrospective cohort analysis. J Clin Hypertens (Greenwich). 2016;18(11):1162\u20137. This retrospective cohort study found significant BP-lower with minoxidil in TRH.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"754_CR79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.109.147686","volume":"56","author":"JJ Oliver","year":"2010","unstructured":"Oliver JJ, Hughes VE, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension. 2010;56(1):62\u20137.","journal-title":"Hypertension"},{"issue":"1","key":"754_CR80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.HYP.28.1.109","volume":"28","author":"JJ Saseen","year":"1996","unstructured":"Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28(1):109\u201314.","journal-title":"Hypertension"},{"issue":"2","key":"754_CR81","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.HYP.0000152079.04553.2c","volume":"45","author":"M Kikuya","year":"2005","unstructured":"Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45(2):240\u20135.","journal-title":"Hypertension"},{"issue":"1","key":"754_CR82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.107.096933","volume":"51","author":"RC Hermida","year":"2008","unstructured":"\u2022 Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51(1):69\u201376. This early prospective study found BP benefits in patients with TRH when the adminsitration of an antihypertensive was changed to bedtime.","journal-title":"Hypertension"},{"issue":"5","key":"754_CR83","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/hr.2015.142","volume":"39","author":"RC Hermida","year":"2016","unstructured":"Hermida RC, Ayala DE, Smolensky MH, Fernandez JR, Mojon A, Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39(5):277\u201392.","journal-title":"Hypertens Res"},{"issue":"6","key":"754_CR84","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","volume":"116","author":"S Oparil","year":"2015","unstructured":"Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074\u201395.","journal-title":"Circ Res"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-017-0754-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-017-0754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-017-0754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T19:05:36Z","timestamp":1602270336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-017-0754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s11906-017-0754-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]},"article-number":"56"}}